Search results for: 'deeper the growth pipeline compani'

09 Nov 2022  |  Global  |  Technology Research

Emerging Therapeutics for Rare Neuromuscular Diseases: Pipeline Analysis

Strategic partnering and new product development will enable better biologics for personalized and targeted treatment

Infographics

×

Muscle weakness, cramps, and impaired musculoskeletal functions that occur due to rare defects in nerve and muscle cells characterize neuromuscular disorders (NMDs). The disorders are largely classified as motor neuron diseases, hereditary ataxias, peripheral nerve disorders, neuromuscular junction transmission disorders, and myopathies. NMDs prese...

The global pharmaceutical industry is continuously evolving. with the rising need for novel therapies in the ever-changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as continuously growing number of cancer cases, market needs are shifting from traditional, small molecules to novel, large-molecule the...

The report provides an overview of the global vaccine market estimating the market size broken down by different segments. Vaccines, though a sub-set of biologics, have a completely different dynamic. Not only are they largely designed for a healthy cohort but are also exponentially influenced by government actions and policies. While old generatio...

Pharmaceutical drug discovery and development processes suffer from declining success rates and a stagnant pipeline. Artificial Intelligence (AI) supported by Big Data could be a key element that can provide an effectual solution. There has been a rapid growth in the data generated within the life sciences and pharmaceutical industries. This stems ...

As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treat...

Despite the term patient centricity gaining currency in the industry, there is a degree of variability in a companies’ approach and strategic priorities. Frost & Sullivan sees digitization playing a critical role in transforming the clinical trial model from traditional, high-cost, and difficult-to-access centralized settings to more patient-centri...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

04 Sep 2018  |  North America  |  Market Research

Digital Transformation in the Pharmaceuticals Industry—Companies-to-Action, 2018

Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities

Infographics

×

Key Issues Addressed

The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally en...

With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...